EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long‐acting cabotegravir and rilpivirine in clinical trials

Parul Patel, Susan L Ford, Mark Baker, Claudia Meyer, Louise Garside, Ronald D'Amico, Rodica Van Solingen-Ristea, Herta Crauwels iD, Joseph W Polli, Ciara Seal, Itziar Yagüe Muñoz, Shanker Thiagarajah und 5 weitere

HIV Medicine · 2023-05 · 24 (5) · 568-579

DOI: 10.1111/hiv.13439 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HIV Medicine, online erschienen am 21.11.2022. Verfasst von Parul Patel und 16 weiteren Autor:innen. Beteiligte Einrichtung: ViiV Healthcare, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Anti-HIV Agents, HIV Infections. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Janssen Research and Development, ViiV Healthcare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Limited data exist on pregnant women living with HIV exposed to cabotegravir + rilpivirine (CAB + RPV). Outcomes in pregnant participants exposed to CAB + RPV, and pharmacokinetic washout data in those exposed to CAB + RPV long‐acting (LA) with live births, are presented.

Methods

Women exposed to one or more doses of CAB + RPV (oral/LA) from ViiV Healthcare‐sponsored phase 2b/3/3b clinical trials and the compassionate use programme who became pregnant were included. Upon pregnancy in the trial programme, CAB + RPV was discontinued, an alternative antiretroviral regimen was initiated, and quarterly pharmacokinetic sampling for 52 weeks post‐last injection was obtained. CAB + RPV continuation or alternative antiretroviral regimen initiation was decided by pregnant compassionate use programme participants and their treating physicians.

Results

As of 31 March 2021, 25 pregnancies following CAB + RPV exposure at conception were reported (five oral, 20 LA), including four who conceived during pharmacokinetic washout following treatment discontinuation. There were eight elective abortions, six miscarriages (five in first trimester), one ectopic pregnancy, and 10 live births (one oral, nine LA), including one infant born with congenital ptosis. Among participants exposed to CAB + RPV LA at conception with live births, plasma CAB and RPV washout concentrations during pregnancy were within the range of those observed in non‐pregnant women.

Conclusion

In this first analysis of pregnancy outcomes following CAB + RPV exposure at conception, 10 live births, including one with congenital anomaly, were reported. Plasma CAB and RPV washout concentrations during pregnancy were within the range of those in non‐pregnant women. Pregnancy surveillance within ViiV Healthcare‐sponsored clinical trials is ongoing, with dedicated pregnancy studies planned.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-HIV AgentsHIV InfectionsFemaleHumansPregnancyRilpivirinePregnancy OutcomeAnti-Retroviral AgentsPyridonesDiketopiperazines

Stichwörter der Autor:innen

HIV-1cabotegravirlong-actingpharmacokineticspregnancyrilpivirine

Substanzen

RilpivirineAnti-HIV AgentsAnti-Retroviral AgentscabotegravirPyridonesDiketopiperazines

Autor:innen und Institutionen

  • ViiV Healthcare, Durham, North Carolina, USA.
  • GlaxoSmithKline, Durham, North Carolina, USA.
  • ViiV Healthcare, Nyon, Switzerland.
  • GlaxoSmithKline, Brentford, UK.
  • PHASTAR, Macclesfield, UK.
  • Janssen Research & Development, Beerse, Belgium.

ORCID-Profile: Herta Crauwels

Förderung

  • Janssen Research and Development
  • ViiV Healthcare

Zitieren

APA

Patel, P., Ford, S. L., Baker, M., Meyer, C., Garside, L., D'Amico, R., Van Solingen-Ristea, R., Crauwels, H., Polli, J. W., Seal, C., Yagüe Muñoz, I., Thiagarajah, S., Birmingham, E., Spreen, W. R., Baugh, B., van Wyk, J., & Vannappagari, V. (2023). Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long‐acting cabotegravir and rilpivirine in clinical trials. HIV Medicine, 24(5), 568-579. https://doi.org/10.1111/hiv.13439

Vancouver

Patel P, Ford SL, Baker M, Meyer C, Garside L, D'Amico R, et al. Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long‐acting cabotegravir and rilpivirine in clinical trials. HIV Medicine. 2023;24(5):568-579. doi:10.1111/hiv.13439

BibTeX
@article{Patel2023,
  author = {Patel, Parul and Ford, Susan L and Baker, Mark and Meyer, Claudia and Garside, Louise and D'Amico, Ronald and Van Solingen-Ristea, Rodica and Crauwels, Herta and Polli, Joseph W and Seal, Ciara and Yagüe Muñoz, Itziar and Thiagarajah, Shanker and Birmingham, Eileen and Spreen, William R and Baugh, Bryan and van Wyk, Jean and Vannappagari, Vani},
  title = {Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long‐acting cabotegravir and rilpivirine in clinical trials},
  journal = {HIV Medicine},
  year = {2023},
  volume = {24},
  number = {5},
  pages = {568--579},
  doi = {10.1111/hiv.13439}
}
Kostenlos starten →